Evidence map›Paper›PMID 31083486›Full record

ArticleGenes2019

Outcome Definition Influences the Relationship Between Genetic Polymorphisms of

Zulfan Zazuli, Leila S Otten, Britt I Drögemöller, Mara Medeiros, Jose G Monzon, Galen E B Wright, Christian K Kollmannsberger, Philippe L Bedard, Zhuo Chen, Karen A Gelmon and 8 more

Open access · goldAbstract read
In one paragraph

Article in Genes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted.International journal of molecular sciences · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 4 countries.

Zulfan ZazuliDepartment of Respiratory Medicine, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. z.zazuli@amc.uva.nl.
Leila S OttenDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3512 JE Utrecht, The Netherlands. l.s.otten@students.uu.nl.
Britt I DrögemöllerBritish Columbia Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada. bdrogemoller@cmmt.ubc.ca.
Mara MedeirosNephrology Research Unit, Hospital Infantil de México Federico Gómez, Mexico City 06720, Mexico. medeiro.mara@gmail.com.
Jose G MonzonDepartment of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada. jgmonzon@ucalgary.ca.
Galen E B WrightBritish Columbia Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada. gwright@cmmt.ubc.ca.
Christian K KollmannsbergerBC Cancer Agency and University of British Columbia, Vancouver, BC V6T 1Z4, Canada. ckollmannsberger@bccancer.bc.ca.
Philippe L BedardPrincess Margaret Cancer Centre and University of Toronto, Toronto, ON M5S, Canada. philippe.bedard@uhn.ca.
Zhuo ChenMedical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre-University Health Network and University of Toronto, Toronto, ON M5S, Canada. Zhuo.Chen@uhnresearch.ca.
Karen A GelmonBC Cancer Agency and University of British Columbia, Vancouver, BC V6T 1Z4, Canada. kgelmon@bccancer.bc.ca.
Nicole McGoldrickPharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, BC V6H 3N1, Canada. nicolemcgoldrick@hotmail.com.
Abhijat KitchluDivision of Nephrology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON M5S, Canada. Abhijat.Kitchlu@uhn.ca.
Susanne J H VijverbergDepartment of Respiratory Medicine, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. s.j.vijverberg@amsterdamumc.nl.
Rosalinde MasereeuwDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3512 JE Utrecht, The Netherlands. R.Masereeuw@uu.nl.
Colin J D RossBritish Columbia Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada. colin.ross@ubc.ca.
Geoffrey LiuMedical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre-University Health Network and University of Toronto, Toronto, ON M5S, Canada. Geoffrey.Liu@uhn.ca.
Bruce C CarletonPharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, BC V6H 3N1, Canada. bcarleton@popi.ubc.ca.
Anke H Maitland-van der ZeeDepartment of Respiratory Medicine, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. a.h.maitland@amsterdamumc.nl.
University of British Columbia · CAUniversity Health Network · CAAmsterdam University Medical Centers · NLBC Cancer Agency · CAUtrecht University · NLBandung Institute of Technology · IDBC Children's Hospital · CAHospital Infantil de México Federico Gómez · MXOccupational Cancer Research Centre · CAUniversity of Toronto · CA

Funding

CIHR CRI-88362CIHR TD1 137714CIHR TD2 117588
6 · The paper itself

Abstract

Although previous research identified candidate genetic polymorphisms associated with cisplatin nephrotoxicity, varying outcome definitions potentially contributed to the variability in the effect size and direction of this relationship. We selected genetic variants that have been significantly associated with cisplatin-induced nephrotoxicity in more than one published study (

Indexed as

Acute Kidney InjuryAdultBiomarkers, PharmacologicalCisplatinCreatinineDNA-Binding ProteinsEndonucleasesGene FrequencyGlomerular Filtration RateHumansKidneyMaleMiddle AgedNeoplasms, Germ Cell and EmbryonalOrganic Cation Transporter 2PharmacogeneticsBiomarkers, PharmacologicalCisplatinCreatinineDNA-Binding ProteinsEndonucleasesERCC1 protein, humanERCC2 protein, humanOrganic Cation Transporter 2SLC22A2 protein, humanXeroderma Pigmentosum Group D Proteincisplatingenetic polymorphismskidney injurynephrotoxicitypharmacogenetics

Identifiers

PMID31083486
PMCPMC6562793
OpenAlexW2944804656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.